No Detail Found!

Study on the clinical effects of targeted therapy on elderly patients with gastric cancer

Author(s)
Lifei Gao Department of General Surgery, Cangzhou Central Hospital,Cangzhou,China
Wei Li Department of General Surgery, Cangzhou Central Hospital,Cangzhou,China
Yagang Liu Department of General Surgery, Cangzhou Central Hospital,Cangzhou,China
Cui Zhang Department of General Surgery, Cangzhou Central Hospital,Cangzhou,China
Weina Gao Department of Endocrinology, Cangzhou Central Hospital,Cangzhou,China
Liang Wang Department of General Surgery, Cangzhou Central Hospital,Cangzhou,China
Abstract
To explore the clinical effects of targeted drug therapy on elderly patients with gastric cancer. Totally 200 metastatic gastric cancer patients who came to our hospital from January 2017 to January 2020 were selected and randomized into four groups, with 50 patients in each group. Bevacizumab (Group I), apatinib (Group II), and recombinant human endostatin (Group III) adopted respectively. While the control group received no targeted drug. Clinical data and clinical effect was collected and compared. After the therapy, the vascular endothelial growth factor (VEGF), soluble vascular endothelial growth factor receptor-2 (sVEGFR2) and human epithelial growth factor receptor-2 (HER2) positive detection of Group I, Group II, and Group III were better than the control group (P<0.05). In addition, the therapeutic effects of Group I, Group II, and Group III were higher and the incidence of adverse reactions was lower than the control group (P<0.05). Targeted drugs have obvious clinical effects in gastric cancer. It can effectively inhibit tumor growth and reduce the occurrence of complications, which is worthy of extensive clinical application and promotion.
Publication Details
Page(s) 2041-2045
Published Journal: Pakistan Journal of Pharmaceutical Sciences, Volume: 34, Issue: S5, Year: 2021

Request the full text from PASTIC

Keywords
targeted drugs, apatinib, Bevacizumab, recombinant human endostatin, Gastric cancer
References
Arjaans M,Oude Munnink TH,Oosting SF,Terwisscha van Scheltinga AG,Gietema JA,Garbacik ET,Timmer-Bosscha H,Lub-de Hooge MN,Schröder CP,de Vries EG CP .2013 .Bevacizumab-induced normalization of blood vessels in tumors hampers antibody uptake. Cancer Res, 73(11) : 3347-55.
Choi AH,Kim J,Chao J .2015 .Perioperative chemotherapy for resectable gastric cancer: MAGIC and beyond. World J. Gastroenterol., 21(24) : 7343-8.
De Sol A,Cirocchi R,Di Patrizi MS,Boccolini A,Barillaro I,Cacurri A,Grassi V,Corsi A,Renzi C,Giuliani D,Coccetta M,Avenia N M .2015 .The measurement of amylase in drain fluid for the detection of pancreatic fistula after gastric cancer surgery: An interim analysis. World J. Surg, 19(13) : 65.
Guggenheim DE and Shah MA .2013 .Gastric cancer epidemiology and risk factors. J. Surg, 107(3) : 230-236.
Johnson K,Gomez A,Burton J,White D,Chakravarty A,Schmid A,Bottino D A .2019 .Directional inconsistency between response evaluation criteria in solid tumors (RECIST) time to progression and response speed and depth. Eur. J. Cance., 109 : 196-203.
Khan U,Shah MA U .2019 .Ramucirumab for the treatment of gastric or gastro-esophageal junction cancer. Expert. Opin. Biol. Ther, 19(11) : 1135-1141.
Kulig P,Sierzega M,Pietruszka S,Pach R,Kołodziejczyk P,Kulig J,Richter P .2020 .Types and implications of abdominal fluid collections following gastric cancer surgery. Acta. Chir, 120(5) : 315-320.
Lerut T,Moons J,Coosemans W,Van Raemdonck D,De Leyn P,Decaluwé H,Decker G,Nafteux P .2009 .Postoperative complications after transthoracic esophagectomy for cancer of the esophagus and gastro esophageal junction are correlated with early cancer recurrence: Role of systematic grading of complications using the modified Clavien classification. , 250(5) : 798-807.
Li F,Liao Z,Zhang C,Zhao J,Xing R,Teng S,Zhang J,Yang Y,Yang J .2018 .Apatinib as targeted therapy for sarcoma. Oncotarget, 9(36) : 24548-24560.
Li K,Shi M,Qin S M .2018 .Current status and study progress of recombinant human endostatin in cancer treatment. Oncol. The., 6(1) : 21-43.
Li Q,Xu X,Su D,Zhou T,Wang G,Li Z G .2019 .Long-term survival of an elderly patient with advanced gastric cancer after combination therapy: A case report and literature review. BMC Cancer, 19(1) : 459.
Liu Y,Tu L,Wang L,Long J,Wang J,Wang Y,Luo F,Cao D F .2016 .The accumulation of macrophages attenuates the effect of recombinant human endostatin on lung cancer. Onco. Targets. Ther., 9 : 6581-6595.
Mawalla B,Yuan X,Luo X,Chalya PL .2018 .Treatment outcome of anti-angiogenesis through VEGF-pathway in the management of gastric cancer: a systematic review of phase II and III clinical trials. BMC Res Notes, 11(1) : 21.
Ohtsu A,Shah MA,Van Cutsem E,Rha SY,Sawaki A,Park SR,Lim HY,Yamada Y,Wu J,Langer B,Starnawski M,Kang YK M .2011 .Bevacizumab in combination with chemotherapy as first-line therapy in advanced gastric cancer: A randomized, double-blind, placebo-controlled phase III study. J. Clin. Oncol., 29(30) : 3968-76.
Ono H,Yao K,Fujishiro M,Oda I,Nimura S,Yahagi N,Iishi H,Oka M,Ajioka Y,Ichinose M,Matsui T .2016 .Guidelines for endoscopic submucosal dissection and endoscopic mucosal resection for early gastric cancer. Dig. Endosc, 28(1) : 3-15.
Pellino A,Riello E,Nappo F,Brignola S,Murgioni S,Djaballah SA,Lonardi S,Zagonel V,Rugge M,Loupakis F,Fassan M .2019 .Targeted therapies in metastatic gastric cancer: Current knowledge and future perspectives. World J. Gastroenterol., 25(38) : 5773-5788.
Roviello G,Ravelli A,Fiaschi AI,Cappelletti MR,Gobbi A,Senti C,Zanotti L,Polom K,Reynolds AR,Fox SB,Generali D SB .2016 .Apatinib for the treatment of gastric cancer. Expert Rev. Gastroenterol. Hepatol., 10(8) : 887-92.
Yamaguchi T,Fushida S,Yamamoto Y,Tsukada T,Kinoshita J,Oyama K,Miyashita T,Tajima H,Ninomiya I,Munesue S,Harashima A,Harada S,Yamamoto H,Ohta T H .2016 .Tumor-associated macrophages of the M2 phenotype contribute to progression in gastric cancer with peritoneal dissemination. Gastric Cancer, 19(4) : 1052-1065.
Zou G,Zhang X,Wang L,Li X,Xie T,Zhao J,Yan J,Wang L,Ye H,Jiao S,Xiang R,Shi Y .2020 .Herb-sourced emodin inhibits angiogenesis of breast cancer by targeting VEGFA transcription. Theranostics, 10(15) : 6839-6853.
0

Citations

0

Downloads

13

Views